Dapagliflozin (BMS-512148)

For research use only.

Catalog No.S1548

23 publications

Dapagliflozin (BMS-512148) Chemical Structure

CAS No. 461432-26-8

Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 280 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dapagliflozin (BMS-512148) has been cited by 23 publications

Purity & Quality Control

Choose Selective SGLT Inhibitors

Biological Activity

Description Dapagliflozin (BMS-512148) is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 4.
Features More potent stimulator of glucosuria than other SGLT2 inhibitors.
Targets
hSGLT2 [1]
(CHO cells)
1.1 nM(EC50)
In vitro

Dapagliflozin is not sensitive to hSGLT1 with a 1200-fold IC50. [1] Dapagliflozin is 32-fold more potent than phlorizin against hSGLT2 but 4-fold less than phlorizin against hSGLT1. Dapagliflozin is highly selective versus GLUT transporters and displays 8–9% inhibition in protein-free buffer at 20 μM and virtually no inhibition in the presence of 4% bovine serum albumin. [2] Dapagliflozin has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin is stable in rat, dog, monkey, and human serum at 10 μM. Dapagliflozin shows no inhibitory responses or induction to human P450 enzymes. The in vitro metabolic pathways Dapagliflozin are glucuronidation, hydroxylation, and O-deethylation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells MnzuSpVv[3Srb36gZZN{[Xl? MUmyJIg> MoXsTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IGuxOGNe[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMES5JO69VQ>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR|NEmwPUc,OjB2M{S5NFk9N2F-
CHOK1 cells NGHDNZlHfW6ldHnvckBie3OjeR?= MVyzJIg> NFraN5pKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF;LNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuxOGNeNUGPRzD1dJRic2ViYX\0[ZIhOyCqcoOgZpkhdWmlcn;i[ZRiKHOlaX70bYxt[XSrb36gZ492dnSrbnegZY5idHm|aYOsJGlEPTB;MD6wNFEh|ryP NFP0eZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi0NlYyQCd-MkS4OFI3OTh:L3G+
HEK293.ETN cells M2nrTWZ2dmO2aX;uJIF{e2G7 MVmxMlUhcA>? NGHF[VFKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJJRz[W6|ZnXjeIVlKGmwIFjFT|I6Oy6HVF6gZ4VtdHNiYYPz[ZN{\WRiYYOgRW1IKHWydHHr[UBi\nSncjCxMlUhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yME[3JO69VQ>? MkW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OU[zO|QoRjF7OEm2N|c1RC:jPh?=
COS-7 cells NY\Cb2VVTnWwY4Tpc44h[XO|YYm= M2nGSlIhcA>? MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFRzIITyZY5{\mWldHXkJIlvKEORUz23JINmdGy|IHHzd4V{e2WmIHHzJGFOTyC3cIThb4Uh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjh7IN88US=> Mlq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OU[zO|QoRjF7OEm2N|c1RC:jPh?=
CHO MXLGeY5kfGmxbjDhd5NigQ>? NWP2U21xUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R31CVUdiYXPjeY12dGG2aX;uMEBGSzVyIE2gNE4xODFzIN88UU4> NWHhNWRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOlA3OThpPkG4NlYxPjF6PD;hQi=>
CHO MnL6SpVv[3Srb36gZZN{[Xl? MoO2TY5pcWKrdHnvckBw\iC{YYSgV2dNXDJiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHsyPEOfQV3HJIFk[3WvdXzheIlwdixiRVO1NEA:KDBwMECzJO69VS5? MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NkC2NVgoRjF6Mk[wOlE5RC:jPh?=
CHO MkT0SpVv[3Srb36gZZN{[Xl? NF7ZTnpKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYWFOTyCjY3P1cZVt[XSrb36sJGVEPTBiPTCxMlM6KM7:TT6= NH;Fd|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK2NFYyQCd-MUiyOlA3OTh:L3G+
HEK293.ETN NX3tZWJiTnWwY4Tpc44h[XO|YYm= NUPYSpJ[UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iSFXLNlk{NkWWTjDj[YxteyCjc4Pld5Nm\CCjczDt[ZRpgWxvYXzwbIEuTC2dVT2xOGNe\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wNFY4KM7:TT6= NV\GeG1tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NFA{OThpPkG5O|AxOzF6PD;hQi=>
COS7 NGjwTGZHfW6ldHnvckBie3OjeR?= MlewTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{Bu\XSqeXytZYxxcGFvRD3bWU0yPEOfZ3z1Z49xgXKjbn;zbYRmKHWydHHr[UBjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE45QDVizszNMi=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdyMEOxPEc,OTl5MECzNVg9N2F-
HEK293 MV3GeY5kfGmxbjDhd5NigQ>? NIqz[FNKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZWGucHjhMY1mfGi7bHfseYNweHm{YX7vd4ll\SC3cIThb4UtKEmFNUCgQUAxNjhzIN88UU4> NUXwWox2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFU1OzVpPkG5O|g2PDN3PD;hQi=>
CHO NWDJRZNGTnWwY4Tpc44h[XO|YYm= MoLpNkBpenN? NGfZeJhKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC|b3TpeY0u\GWyZX7k[Y51KG2ndHj5cE1idHCqYT3EMXtWNTF2Q23ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|LDDJR|UxKD1iMD6wNFE1KM7:TT6= MmjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEm2OVMoRjJyMUS5OlU{RC:jPh?=
CHO MVvGeY5kfGmxbjDhd5NigQ>? NVHsc5JbOiCqcoO= NFnCbmlKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC|b3TpeY0u\GWyZX7k[Y51KG2ndHj5cE1idHCqYT3EMXtWNTF2Q23ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|LDDJR|UxKD1iMT6yJO69VS5? NHjFfJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0PVY2Oyd-MkCxOFk3PTN:L3G+
CHO MWDGeY5kfGmxbjDhd5NigQ>? NGHab5hKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGPHUHQzKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkCwNFQ6KM7:TT6= MlnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzOEG0PFYoRjJyMUixOFg3RC:jPh?=
HEK293 MWPGeY5kfGmxbjDhd5NigQ>? MX[xMlUhcHK| NIfGTHBKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbNVREZWGucHjhMY1mfGi7bD3EMYdtfWOxcInyZY5we2mmZTD1dJRic2ViYX\0[ZIhOS53IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFA3PyEQvF2u NELDd5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW3OlU4QCd-MkC1O|Y2Pzh:L3G+
COS7 NUDxO|V[TnWwY4Tpc44h[XO|YYm= MWqyJIhzew>? NEfNUWdKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S12jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDJiaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD64PUDPxE1w NEH5c2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW3OlU4QCd-MkC1O|Y2Pzh:L3G+
CHO MXzGeY5kfGmxbjDhd5NigQ>? M1TPRVIhcHK| MkPCTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IIPv[Il2dS2mZYDlcoRmdnRiW{G0R30u[WyyaHGtcYV1cHmuLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAzKGi{czDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiRVO1NEA:KDBwMECzJO69VS5? M{XC[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUK4OVkzLz5{MUGyPFU6OjxxYU6=
CHO M{LrT2Z2dmO2aX;uJIF{e2G7 MoK1NkBpenN? NHrW[Y9KdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgd49lcXWvLXTldIVv\GWwdDDbNVREZS2jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDJiaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDFR|UxKD1iMD60Nlg2KM7:TT6= M4TKUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUK4OVkzLz5{MUGyPFU6OjxxYU6=
CHO NILuPWVHfW6ldHnvckBie3OjeR?= NXr3cJdIOiCqcoO= NVHLcVFNUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R31idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidYD0ZYtmKGGodHXyJFIhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwJF0hOC5yMEC0PUDPxE1w MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzOUOzNFgoRjJzMUmzN|A5RC:jPh?=
CHO MV\GeY5kfGmxbjDhd5NigQ>? MnTROlAhdWmwcx?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXT3hcJBp[S2vZYTofYwuTC2pbIXjc5B6emGwb4Pp[IUhfHKjboPwc5J1KGGodHXyJFYxKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IECuNFA1KM7:TT6= MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUixNlQoRjJzM{m4NVI1RC:jPh?=
CHO M{n0cWZ2dmO2aX;uJIF{e2G7 NEPBXoo3OCCvaX7z MnfUTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q22tZYxxcGFvbXX0bJltNURvZ3z1Z49xgXKjbn;zbYRmKHS{YX7zdI9zfCCjZoTldkA3OCCvaX7zJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnegbY4heHKnc3XuZ4Uhd2ZiMUCwKUBxdGG|bXGsJGlEPTBiPTCwMlAzOiEQvF2u NYLxSpVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzPVgyOjRpPkKxN|k5OTJ2PD;hQi=>
CHO NVyyO2FMTnWwY4Tpc44h[XO|YYm= Mn[xOlAhdWmwcx?= MlLyTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q22tZYxxcGFvbXX0bJltNURvZ3z1Z49xgXKjbn;zbYRmKHS{YX7zdI9zfCCjZoTldkA3OCCvaX7zJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCwMlM4KM7:TT6= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN7OEGyOEc,OjF|OUixNlQ9N2F-
CHO MkfvSpVv[3Srb36gZZN{[Xl? MlvLOlAhdWmwcx?= MVHJcohq[mm2aX;uJI9nKFOJTGS2JIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCdMUTDYU1idHCqYT3t[ZRpgWxvRD3ncJVkd3C7cnHuc5Nq\GVidILhcpNxd3K2IHHmeIVzKDZyIH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvOzhizszNMi=> MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OUixNlQoRjJzM{m4NVI1RC:jPh?=
CHO M1rSTmZ2dmO2aX;uJIF{e2G7 MVuyJIhzew>? NFOz[lBKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgX|E1S11vYXzwbIEudWW2aInsMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGW{LDDJR|UxKD1iMD6wNFA1QSEQvF2u MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVzNECxOEc,OjF3MUSwNVQ9N2F-
CHO MnfmSpVv[3Srb36gZZN{[Xl? M2nENlYxKG2rboO= MkHDTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhYzF2Q22tS4x2[2:|ZTD1dJRic2VidYPpcochYzF2Q22tcYV1cHmuIHfseYNweHm{YX7vd4ll\SCjZoTldkA3OCCvaX7zJIJ6KG2rY4LvZoV1[SCybHH0[UBkd3WwdHnu[{whUUN3MDC9JFAvODB|IN88UU4> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV4NUS5O{c,OjF3NkW0PVc9N2F-
CHO MXfGeY5kfGmxbjDhd5NigQ>? MlXxTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KHW|aX7nJI1mfGi7bD3hcJBp[S2GLXfseYNweHm{YX7vd4ll\SCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvODBzM{Wg{txONg>? NIfhbVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc6PCd-MkG1PVI4QTR:L3G+
COS7 NIrZVHhHfW6ldHnvckBie3OjeR?= MXqyJIhzew>? NFq4ephKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDU3M4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gX|E1S11vbXX0bJltNWGucHjhMWQu\2y3Y3;wfZJidm:|aXTlJJVxfGGtZTDh[pRmeiB{IHjyd{BjgSC|Y3nueIltdGG2aX;uJINwfW62aX7nJIlvKHC{ZYPlcoNmKG:oIEK1JEUhcHWvYX6gdIxie22jLDDJR|UxKD1iMD6wNFMzKM7:TT6= Mn\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{eyOlYoRjJzN{O3NlY3RC:jPh?=
293 NU\qcIg{TnWwY4Tpc44h[XO|YYm= NFHyVogyNjViaILz NF7ZNoVKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSxJIV5eHKnc4Pl[EBqdiCqdX3hckAzQTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBcOTSFXT3t[ZRpgWxvYXzwbIEuTC2pbIXjc5B6emGwb4Pp[IUhfXC2YXvlJIFnfGW{IEGuOUBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCrbjDwdoV{\W6lZTDv[kAzPSBnIHj1cYFvKHCuYYPtZUwhUUN3MDC9JFMvOSEQvF2u MlzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{eyOlYoRjJzN{O3NlY3RC:jPh?=
CHO MYDGeY5kfGmxbjDhd5NigQ>? MYWyJIhzew>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNIVFR{IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHsyPEOfLXzhZoVt\WRiQV3HJIFnfGW{IEKgbJJ{KGK7IHzpdZVq\CC|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE4xODF|NTFOwG0v Mo\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NkiyN|koRjJzOE[4NlM6RC:jPh?=
CHO NYHafGtLTnWwY4Tpc44h[XO|YYm= MkXJNkBpenN? M2PsT2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDbNVREZS2jbIDoZU1u\XSqeXytSE1odHWlb4D5doFvd3OrZHWgeZB1[WunIHHmeIVzKDJiaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxKD1iMD6wNFA1QSEQvF2u MkTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7ME[5OVMoRjJzOUC2PVU{RC:jPh?=
CHO-K1 NGPiUWZHfW6ldHnvckBie3OjeR?= MlrwTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRLVuxJINmdGy|IHL5JHsyPEOfQV3HJJVxfGGtZTDhd5NigSxiSVO1NEA:KDBwMECxN{DPxE1w MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUKyOVUoRjJ{NkWyNlU2RC:jPh?=
CHO-K1 Mn3HSpVv[3Srb36gZZN{[Xl? NX\ERoVWUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNUBmgHC{ZYPz[YQhcW5iQ1jPMWsyKGOnbHzzJIJ6KFtzNFPdRW1IKHWydHHr[UBie3OjeTygTWM2OCB;IECuPEDPxE1w NV3KdHZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVIzPTVpPkKyOlUzOjV3PD;hQi=>
CHO-K1 MnnlSpVv[3Srb36gZZN{[Xl? M2P2UVEzOCCvaX7z MlPMTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRLVuxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOTJyIH3pcpMh[XRiM{eg[IVoSyCkeTDbNVREZS2DTVegeZB1[WunIHHzd4F6NCCHQ{WwJF0hOC5yMEK0JO69VS5? NFrpfY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkixPFA1OCd-MkK4NVgxPDB:L3G+
CHO-K1 M4iwZWZ2dmO2aX;uJIF{e2G7 M2POXFEzOCCvaX7z MmXFTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRLVuxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOTJyIH3pcpMh[XRiM{eg[IVoSyCkeTDbNVREZS2DTVegeZB1[WunIHHzd4F6NCCHQ{WwJF0hOC53OUOg{txONg>? NEL4epk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkixPFA1OCd-MkK4NVgxPDB:L3G+
CHO MmnoSpVv[3Srb36gZZN{[Xl? NVnZOGpsPDVibXnudy=> M3nvT2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEKg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxZHn1cU1l\XCnbnTlcpQhYzF2Q23t[ZRpgWxvYXzwbIEuTC2pbIXjc5B6emGwb4Pp[IUhfXC2YXvlJIFnfGW{IES1JI1qdnNuIFnDOVAhRSByLkCwNVMh|ryPLh?= NXzybWp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PFk{PTFpPkKyPFg6OzVzPD;hQi=>
CHO MmXkSpVv[3Srb36gZZN{[Xl? M3S5XVQ2KG2rboO= M4iz[2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxZHn1cU1l\XCnbnTlcpQhYzF2Q23t[ZRpgWxvYXzwbIEuTC2pbIXjc5B6emGwb4Pp[IUhfXC2YXvlJIFnfGW{IES1JI1qdnNuIFnDOVAhRSByLkig{txONg>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh6OUO1NUc,OjJ6OEmzOVE9N2F-
CHOK1 MXLGeY5kfGmxbjDhd5NigQ>? M3XpRVMhcHK| M2fMUmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEOKT1uxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiW{G0R30uSU2JIIXweIFs\SCjZoTldkA{KGi{czDifUBucWO{b3LleIEhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDhcoFtgXOrczygTWM2OCB;IECuPFkyKM7:TT6= M3fhfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OESyOlE5Lz5{NEi0NlYyQDxxYU6=
CHO M2PvVWZ2dmO2aX;uJIF{e2G7 M{fjPFIhcHK| NV\3WJJuUW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJHsyPEOfLXHsdIhiNW2ndHj5cE1FNWeudXPvdJlz[W6xc3nk[UB2eHSja3WgZYZ1\XJiMjDodpMh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCwMlAxODR7IN88UU4> NVXXUJpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzQTdpPkK0PVAxOjl5PD;hQi=>
CHO MoDCSpVv[3Srb36gZZN{[Xl? M1P2SlIhcHK| NXLlcJVqS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBnfWyuLXzlcod1cCCqdX3hckBUT0yWMjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhe2:maYXtMYRmeGWwZHXueEBcOTSFXT3hcJBp[S2vZYTofYwuTC2pbIXjc5B6emGwb4Pp[IUhfXC2YXvlJIFnfGW{IEKgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjByNTFOwG0v NFfLZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1NFI2PCd-MkW2OVAzPTR:L3G+
CHO NWjEV3I5TnWwY4Tpc44h[XO|YYm= MWGxNlAhdWmwcx?= NVjK[nk3UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHWydHHr[UBw\iCdMUTDYWFOTyCjZoTldkAyOjBibXnud{BjgSCWb4DDc5VvfCCvZYToc4QtKEmFNUCgQUAxNjByMUWg{txONg>? NHHmTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES0O|c6OSd-Mki0OFc4QTF:L3G+
CHO M33ue2Z2dmO2aX;uJIF{e2G7 MXixNlAhdWmwcx?= MmrvTY5pcWKrdHnvckBw\iCqdX3hckBUT0yWMTDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJJVxfGGtZTDv[kBcOTSFXVHNS{Bi\nSncjCxNlAhdWmwczDifUBVd3CFb4XueEBu\XSqb3SsJGlEPTBiPTCwMlYzQSEQvF2u MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR2N{e5NUc,Ojh2NEe3PVE9N2F-
CHO MkPwSpVv[3Srb36gZZN{[Xl? MnrpNUBpeg>? NVLwdXY4UW6qaXLpeIlwdiCxZjDoeY1idiCVR1zUNkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCdMUTDYWFOTyC3cIThb4Uh[W[2ZYKgNUBpeiCkeTDtbYNzd2KndHGgZ492dnSrbnegcYV1cG:mLDDFR|UxKD1iMD6wNFIh|ryPLh?= NXTwXFdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNVY2PjBpPkK5NlE3PTZyPD;hQi=>
CHO NGW5c5RHfW6ldHnvckBie3OjeR?= M3rxdlEhcHJ? M{fqWmlvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzF2Q23BUWchfXC2YXvlJIFnfGW{IEGgbJIh[nlibXnjdo9j\XSjIHPveY51cW6pIH3leIhw\CxiRVO1NEA:KDBwOE[g{txONg>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJzNkW2NEc,Ojl{MU[1OlA9N2F-
CHO MVvGeY5kfGmxbjDhd5NigQ>? MX[xJIhz NI\YWmxKdmirYnn0bY9vKG:oIH\1cIwudGWwZ4ToJIh2dWGwIGPHUHQzKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iW{G0R30udWW2aInsJIFteGijLVSt[4x2[2:yeYLhco9{cWSnIIXweIFs\SCjZoTldkAyKGi{IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODBzMEWg{txONg>? M{PDXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{[0O|QzLz5{OUe2OFc1OjxxYU6=
HEK293 NFLiOJVHfW6ldHnvckBie3OjeR?= NXLudHBKOTBibXnudy=> NH;ScJRKdmirYnn0bY9vKG:oIHj1cYFvKFOJTGSyJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iW{G0R30uSU2JIIXweIFs\SCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpMh\m:ubH;3[YQh[nliW{G0R30uSU2JIHHk[Il1cW:wIHHu[EBu\WG|dYLl[EBi\nSncjCyJIhzeyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{Bu\XSqb3SsJGlEPTBiPTCwMlAxOTRizszNMi=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl3NE[4Nkc,Ojl7NUS2PFI9N2F-
HEK293 MoG3SpVv[3Srb36gZZN{[Xl? M{HzcVExKG2rboO= M3vmS2lvcGmkaYTpc44hd2ZiaIXtZY4hW0eOVEGg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCdMUTDYU1CVUdidYD0ZYtmKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bnd2yub4fl[EBjgSCdMUTDYU1CVUdiYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEKgbJJ{KGK7IHzpdZVq\CC|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IEGuPFMh|ryPLh?= NIn4e5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm1OFY5Oid-Mkm5OVQ3QDJ:L3G+

... Click to View More Cell Line Experimental Data

In vivo Dapagliflozin reduces blood glucose levels by 55% after 0.1 mg/kg oral dose in hyperglycemic streptozotocin (STZ) rats, which is in part to the metabolic stability conferred by the C-glucoside linkage. Dapagliflozin displays a favorable absorption, distribution, metabolism, and excretion (ADME) profile and is orally bioavailable. [1] Dapagliflozin (1 mg/kg) causes significant dose-dependent glucosuria and increase in urine volume in normal rats over 24 hours post-dose. Dapagliflozin induces increase in urine glucose and urine volume excretion at 6 hours post-dose in Zucker diabetic fatty (ZDF) rats. Dapagliflozin lowers fasting and fed glucose levels in ZDF rats even by 2 weeks of treatment, without any marker of renal or liver toxicity. [2] Dapagliflozin significantly reduces the development of hyperglycaemia, with lowered blood glucose. Dapagliflozin could improve the insulin sensitivity, reduce β-cell mass and the development of impaired pancreatic function. [4]

Protocol

Animal Research:[1]
- Collapse
  • Animal Models: Normal Sprague Dawley rats or streptozotocin induced male Sprague Dawley rats
  • Dosages: 0.01-10 mg/kg (1 mL/kg) followed by a 50% glucose solution (2 g/kg)
  • Administration: Dosed orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.55 mM)
Water Insoluble
Ethanol '17 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5% tween80+50% H2O
For best results, use promptly after mixing.
4.1 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.87
Formula

C21H25ClO6

CAS No. 461432-26-8
Storage powder
in solvent
Synonyms N/A
Smiles CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04724837 Not yet recruiting Drug: Zibotentan|Drug: Dapagliflozin|Drug: Placebo Chronic Kidney Disease AstraZeneca May 31 2021 Phase 2
NCT04445714 Recruiting Drug: dapagliflozin and saxagliptin Type 2 Diabetes Mellitus AstraZeneca April 7 2021 Phase 4
NCT04570865 Not yet recruiting Drug: Dapagliflozin|Device: CardioMEMS Heart Failure Systolic Scripps Health December 1 2020 Phase 4
NCT04534270 Completed Drug: Dapagliflozin Proteinuria Children''s Hospital of Fudan University July 6 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

SGLT Signaling Pathway Map

Related SGLT Products

Tags: buy Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) supplier | purchase Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) cost | Dapagliflozin (BMS-512148) manufacturer | order Dapagliflozin (BMS-512148) | Dapagliflozin (BMS-512148) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID